Avid Bioservices Inc (CDMO)

[biopharm]

such as myeloid-derived suppressor cells (MDSCs), were reduced by more than 40% in the combination with the PS-targeting antibody versus anti-PD-1 alone.

Lots of NEW info being learned in the MOA of PS Targeting as well as the MOA behind Halozyme IP assets that Helen Torley has found out....and seems like a perfect match as Helen may soon find out PS Targeting is required for the combo

2. MDSCs Generation and Expansion during Tumor Progression
Numerous reports published during the last decade described a strong correlation between the development of chronic inflammatory conditions in the tumor microenvironment and generation and expansion of MDSCs [1,2,3,4,18,23,24]. Furthermore, chronic inflammation has been found to be associated with the initiation and progression of various tumors [25]. Although the onset of some other tumors such as malignant melanoma is not generally associated with apparent inflammation, recent publications highlighted the critical importance of particular cytokines and chemokines for their fast progression [26]. Tumor cells are able to produce a variety of inflammatory mediators including granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), stem cell factor (SCF), vascular endothelial growth factor (VEGF), TGF-ß, tumor necrosis factor (TNF)-a, IL-1ß, IL-6, and IL-10 [1,2,3,4,26,27]. The effect of all these factors is combinatorial and dose-dependent. Furthermore, tumor cells can induce the production of these factors by fibroblasts and immune cells in the tumor stroma [1,28]. Moreover, stromal cells can further stimulate the production of inflammatory mediators by tumor cells thereby creating autocrine and paracrine loops in the tumor progression [29]. Altogether, these inflammatory factors can modulate myeloid cells in the tumor microenvironment, and having them delivered distantly to hematopoietic organs can change normal myelopoiesis and skew the differentiation of myeloid cells in favor of MDSCs
...
...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192356/#__ffn_sectitle

https://www.halozyme.com/investors/news-releases/news-release-details/2018/Halozyme-Publication-In-The-Journal-Clinical-Cancer-Research-Highlights-New-Nonclinical-Data-Supporting-Multiple-Effects-Of-PEGPH20-On-The-Tumor-Microenvironment/default.aspx

I wonder who is cross checking MOA of IP assets vs PS Targeting across Big Pharma